Aesica adds development capability at Queenborough with opening of new purpose built facility – Product life cycle services expanded including for high potent and controlled drugs

Apr 11, 2016

5 April 2016: Aesica Pharmaceuticals, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced the doubling of its development capacity – manufacturing multiple drug products up to  Phase III clinical trials at Queenborough. With the addition of the new capabilities, Aesica can now develop and manufacture a customer product from early formulation development through clinical manufacture and into commercialisation – covering all aspects of product life cycle on the one site. This process will now be a seamless end-to-end service offering for the customer The company’s high potent and controlled drugs service offering has been significantly expanded ...

Read More

New brochure from Copley Scientific delivers essential information on its upgraded pharmaceutical testing range

Feb 2, 2016

02 February 2016: Nottingham, UK:The latest version of ‘Quality Solutions for the Testing of Pharmaceuticals’ from Copley Scientific provides detailed information for those seeking assistance with the interpretation and application of regulatory guidance, as well as highlighting new additions to the company’s extensive range. Considered a ‘go to’ resource for expert advice that is rooted in current regulatory guidance and pharmacopoeial chapters, the brand new brochure can be freely downloaded from the Copley website – www.copleyscientific.com, with printed versions available on request fromsales@copleyscientific.co.uk. The 2016 brochure covers the latest international requirements for testing the safety, quality and efficacy of  transdermals, ...

Read More